Novaliq begins patient enrollment for phase 2 trial of CyclASol for dry eye disease

Novaliq has started to enroll patients in a phase 2 trial of CyclASol to treat dry eye disease, the company announced in a press release.

The randomized, double-masked, placebo-controlled multicenter phase 2 trial will evaluate the safety, efficacy and tolerability of topical CyclASol (cyclosporine in semifluorinated alkanes) for the treatment of patients with moderate to severe dry eye disease.

The company estimates a total enrollment of 200 patients at four U.S. sites.

Patients will be placed randomly into one of two CyclASol groups, a placebo group or an open-label cyclosporine A 0.05% emulsion group. Over 4 months, patients will self-administer one drop twice daily and return for examination periodically.